Specifically, AstroRx is a cell therapy product containing functional healthy astrocytes derived from human embryonic stem cells that aim to protect diseased motor neurons. The cells are injected in the patient through the spinal canal.
The company initiated its first ALS clinical trials in March 2018.
Prof. Michel Revel, founder and CEO of the company and winner of both the EMET Prize and the Israel Prize, said that the clinical trial results “provide the confidence needed to move forward” with cohorts B and C, which he said both “hold the potential for a prolonged response.”
Comments are closed.